See more : Kempower Oyj (KEMPOWR.HE) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Rad Laboratories, Inc. (BIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Rad Laboratories, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Churchill Capital Corp VII (CVII-UN) Income Statement Analysis – Financial Results
- Harel Insurance Investments & Financial Services Ltd (HAHRF) Income Statement Analysis – Financial Results
- BCL Enterprises Limited (BCLENTERPR.BO) Income Statement Analysis – Financial Results
- Pine Technology Acquisition Corp. (PTOCW) Income Statement Analysis – Financial Results
- Diamond Electric Holdings Co., Ltd. (6699.T) Income Statement Analysis – Financial Results
Bio-Rad Laboratories, Inc. (BIO)
About Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 | 1989 | 1988 | 1987 | 1986 | 1985 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.67B | 2.80B | 2.92B | 2.55B | 2.31B | 2.29B | 2.16B | 2.07B | 2.02B | 2.18B | 2.13B | 2.07B | 2.07B | 1.93B | 1.78B | 1.76B | 1.46B | 1.27B | 1.18B | 1.09B | 1.00B | 892.72M | 817.51M | 725.88M | 549.50M | 441.90M | 426.90M | 418.80M | 396.60M | 355.30M | 328.60M | 330.30M | 310.70M | 286.70M | 236.30M | 198.90M | 159.50M | 126.60M | 102.30M |
| Cost of Revenue | 1.24B | 1.23B | 1.28B | 1.11B | 1.05B | 1.07B | 972.75M | 930.09M | 897.77M | 996.53M | 954.22M | 908.19M | 895.64M | 835.63M | 784.40M | 801.84M | 669.69M | 561.39M | 534.50M | 479.94M | 437.99M | 383.24M | 356.33M | 300.06M | 227.70M | 181.50M | 169.90M | 164.10M | 155.20M | 139.00M | 134.40M | 124.30M | 122.20M | 113.30M | 95.30M | 81.50M | 63.50M | 52.70M | 45.60M |
| Gross Profit | 1.43B | 1.57B | 1.64B | 1.44B | 1.26B | 1.22B | 1.19B | 1.14B | 1.12B | 1.18B | 1.18B | 1.16B | 1.18B | 1.09B | 999.84M | 962.52M | 791.36M | 712.54M | 646.49M | 610.07M | 565.39M | 509.49M | 461.18M | 425.83M | 321.80M | 260.40M | 257.00M | 254.70M | 241.40M | 216.30M | 194.20M | 206.00M | 188.50M | 173.40M | 141.00M | 117.40M | 96.00M | 73.90M | 56.70M |
| Gross Profit Ratio | 53.58% | 55.93% | 56.14% | 56.48% | 54.38% | 53.46% | 54.97% | 55.03% | 55.54% | 54.18% | 55.26% | 56.11% | 56.81% | 56.64% | 56.04% | 54.55% | 54.16% | 55.93% | 54.74% | 55.97% | 56.35% | 57.07% | 56.41% | 58.66% | 58.56% | 58.93% | 60.20% | 60.82% | 60.87% | 60.88% | 59.10% | 62.37% | 60.67% | 60.48% | 59.67% | 59.02% | 60.19% | 58.37% | 55.43% |
| Research & Development | 226.93M | 256.89M | 271.66M | 226.60M | 202.71M | 199.20M | 250.30M | 205.86M | 192.97M | 220.33M | 210.95M | 214.04M | 186.44M | 172.27M | 163.59M | 159.52M | 140.54M | 123.38M | 115.10M | 108.34M | 94.27M | 82.94M | 76.54M | 68.14M | 51.20M | 41.40M | 46.10M | 39.60M | 34.70M | 30.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 834.78M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 0.00 | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.49M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 820.62M | 827.83M | 879.57M | 800.27M | 824.63M | 833.29M | 808.94M | 816.72M | 761.99M | 808.20M | 798.07M | 682.90M | 696.29M | 635.21M | 601.47M | 591.30M | 507.98M | 438.95M | 416.08M | 378.26M | 325.36M | 289.18M | 272.61M | 247.61M | 194.50M | 167.00M | 164.80M | 155.50M | 150.30M | 132.60M | 167.20M | 177.60M | 154.30M | 138.70M | 112.00M | 91.20M | 74.50M | 58.70M | 46.00M |
| Other Expenses | 0.00 | 44.57M | 26.78M | 24.49M | 26.09M | 36.59M | 12.20M | 14.85M | 11.08M | 13.01M | 12.77M | 21.78M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| Operating Expenses | 1.09B | 1.08B | 1.15B | 1.03B | 1.03B | 1.03B | 1.06B | 1.02B | 954.96M | 1.03B | 1.01B | 896.94M | 882.73M | 807.48M | 765.05M | 808.34M | 648.51M | 562.33M | 531.19M | 486.61M | 419.63M | 372.11M | 349.15M | 359.06M | 273.20M | 229.40M | 230.40M | 213.00M | 201.70M | 179.60M | 183.80M | 191.50M | 166.40M | 149.00M | 119.90M | 97.60M | 79.60M | 62.00M | 48.00M |
| Cost & Expenses | 2.29B | 2.32B | 2.43B | 2.13B | 2.08B | 2.10B | 2.03B | 1.95B | 1.85B | 2.03B | 1.96B | 1.81B | 1.78B | 1.64B | 1.55B | 1.61B | 1.32B | 1.12B | 1.07B | 966.55M | 857.62M | 755.35M | 705.48M | 659.12M | 500.90M | 410.90M | 400.30M | 377.10M | 356.90M | 318.60M | 318.20M | 315.80M | 288.60M | 262.30M | 215.20M | 179.10M | 143.10M | 114.70M | 93.60M |
| Interest Income | 100.90M | 58.00M | 18.90M | 18.20M | 30.50M | 26.60M | 19.10M | 14.70M | 10.10M | 13.50M | 13.40M | 11.40M | 8.20M | 5.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 49.44M | 38.11M | 1.55M | 21.86M | 23.42M | 23.96M | 21.91M | 21.94M | 21.69M | 22.13M | 61.27M | 49.26M | 53.14M | 63.72M | 47.02M | 32.11M | 31.61M | 32.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 145.90M | 177.20M | 176.90M | 175.20M | 174.50M | 138.10M | 148.70M | 142.90M | 131.85M | 149.89M | 147.16M | 130.42M | 120.96M | 108.91M | 101.68M | 97.09M | 67.30M | 55.40M | 61.00M | 56.20M | 42.00M | 38.00M | 41.30M | 43.31M | 27.50M | 21.00M | 19.50M | 17.90M | 16.70M | 16.80M | 16.60M | 13.90M | 12.10M | 10.30M | 7.90M | 6.40M | 5.10M | 3.30M | 2.00M |
| EBITDA | -608.26M | -4.49B | 5.63B | 5.10B | 2.46B | 674.72M | 269.52M | 206.40M | 299.34M | 303.59M | 305.26M | 404.44M | 409.90M | 392.90M | 334.56M | 272.06M | 219.75M | 229.40M | 176.30M | 173.75M | 189.43M | 180.14M | 153.33M | 110.08M | 76.09M | 52.12M | 46.10M | 56.90M | 56.40M | 53.50M | 27.00M | 28.40M | 34.20M | 34.70M | 29.00M | 26.20M | 21.50M | 15.20M | 10.70M |
| EBITDA Ratio | -22.77% | 23.71% | 22.24% | 22.53% | 16.87% | 16.01% | 13.38% | 13.21% | 15.33% | 14.39% | 15.44% | 20.12% | 20.07% | 20.39% | 18.86% | 13.77% | 13.73% | 14.27% | 14.02% | 17.03% | 18.82% | 20.18% | 21.56% | 13.88% | 17.54% | 10.23% | 11.43% | 14.73% | 14.65% | 16.92% | 7.36% | 1.82% | 11.26% | 12.07% | 11.89% | 12.82% | 13.35% | 12.16% | 10.07% |
| Operating Income | 365.70M | 482.62M | 489.43M | 410.96M | 229.66M | -108.64M | 116.65M | 53.19M | 166.71M | 149.98M | 169.46M | 264.11M | 295.16M | 284.01M | 230.99M | 182.94M | 135.19M | 146.11M | 115.30M | 108.85M | 145.76M | 137.38M | 112.03M | 66.77M | 48.60M | 31.00M | 26.60M | 41.70M | 39.70M | 36.70M | 10.40M | 14.50M | 22.10M | 24.40M | 21.10M | 19.80M | 16.40M | 11.90M | 8.70M |
| Operating Income Ratio | 13.69% | 17.22% | 16.75% | 16.14% | 9.93% | -4.74% | 5.40% | 2.57% | 8.26% | 6.90% | 7.95% | 12.76% | 14.23% | 14.74% | 12.95% | 10.37% | 9.25% | 11.47% | 9.76% | 9.99% | 14.53% | 15.39% | 13.70% | 9.20% | 8.84% | 7.02% | 6.23% | 9.96% | 10.01% | 10.33% | 3.16% | 4.39% | 7.11% | 8.51% | 8.93% | 9.95% | 10.28% | 9.40% | 8.50% |
| Total Other Income/Expenses | -1.22B | -5.19B | 4.95B | 4.49B | 2.03B | 319.39M | -15.35M | -73.94M | -20.86M | -18.43M | -57.07M | -34.27M | -59.39M | -63.73M | -45.16M | -40.10M | -14.35M | -4.08M | -21.93M | -11.52M | -32.07M | -32.97M | -47.06M | -21.32M | -32.18M | 3.23M | -3.80M | -2.50M | -6.10M | -12.70M | -5.70M | 13.10M | -8.50M | -7.20M | -5.30M | -4.60M | -3.70M | -2.40M | -2.70M |
| Income Before Tax | -850.10M | -4.70B | 5.44B | 4.91B | 2.26B | 507.36M | 97.81M | 41.56M | 145.85M | 131.56M | 112.39M | 231.58M | 235.76M | 220.28M | 185.83M | 142.84M | 120.84M | 142.03M | 93.37M | 97.33M | 113.69M | 104.41M | 64.97M | 45.44M | 16.40M | 34.20M | 22.80M | 36.50M | 33.60M | 24.00M | 4.70M | 27.60M | 13.60M | 17.20M | 15.80M | 15.20M | 12.70M | 9.50M | 6.00M |
| Income Before Tax Ratio | -31.82% | -167.87% | 186.08% | 192.79% | 97.81% | 22.15% | 4.53% | 2.01% | 7.22% | 6.05% | 5.27% | 11.19% | 11.37% | 11.43% | 10.42% | 8.10% | 8.27% | 11.15% | 7.91% | 8.93% | 11.33% | 11.70% | 7.95% | 6.26% | 2.98% | 7.74% | 5.34% | 8.72% | 8.47% | 6.75% | 1.43% | 8.36% | 4.38% | 6.00% | 6.69% | 7.64% | 7.96% | 7.50% | 5.87% |
| Income Tax Expense | -212.78M | -1.08B | 1.19B | 1.10B | 502.41M | 146.36M | -16.94M | 13.44M | 32.75M | 42.71M | 34.57M | 62.28M | 57.74M | 33.35M | 36.67M | 44.58M | 26.55M | 38.76M | 15.79M | 31.04M | 37.52M | 36.54M | 20.79M | 13.63M | 4.70M | 9.90M | 6.40M | 9.10M | 8.40M | 8.40M | 1.90M | 12.00M | 5.40M | 6.50M | 5.70M | 5.70M | 5.00M | 3.40M | 1.70M |
| Net Income | -637.32M | -3.63B | 4.25B | 3.81B | 1.76B | 361.00M | 114.74M | 28.13M | 113.09M | 88.85M | 77.79M | 169.23M | 178.22M | 185.49M | 144.62M | 89.51M | 92.99M | 103.26M | 81.55M | 68.24M | 76.17M | 67.86M | 44.18M | 31.10M | 11.70M | 24.30M | 16.40M | 26.20M | 25.20M | 15.60M | 2.80M | 15.60M | 8.20M | 10.70M | 10.10M | 9.50M | 7.70M | 6.10M | 4.30M |
| Net Income Ratio | -23.86% | -129.45% | 145.57% | 149.83% | 76.08% | 15.76% | 5.31% | 1.36% | 5.60% | 4.08% | 3.65% | 8.18% | 8.60% | 9.63% | 8.11% | 5.07% | 6.36% | 8.11% | 6.91% | 6.26% | 7.59% | 7.60% | 5.40% | 4.28% | 2.13% | 5.50% | 3.84% | 6.26% | 6.35% | 4.39% | 0.85% | 4.72% | 2.64% | 3.73% | 4.27% | 4.78% | 4.83% | 4.82% | 4.20% |
| EPS | -21.82 | -121.79 | 142.61 | 127.86 | 58.93 | 12.10 | 4.12 | 0.88 | 3.74 | 3.08 | 2.72 | 5.85 | 6.39 | 6.70 | 5.28 | 3.30 | 3.48 | 3.92 | 3.13 | 2.65 | 3.00 | 2.70 | 1.79 | 1.27 | 0.49 | 0.99 | 0.67 | 1.07 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| EPS Diluted | -21.82 | -121.79 | 140.83 | 126.20 | 58.27 | 11.94 | 4.07 | 0.88 | 3.71 | 3.05 | 2.69 | 5.78 | 6.29 | 6.59 | 5.20 | 3.24 | 3.41 | 3.83 | 3.06 | 2.58 | 2.90 | 2.61 | 1.74 | 1.27 | 0.48 | 0.99 | 0.66 | 1.05 | 1.03 | 0.64 | 0.12 | 0.66 | 0.35 | 0.46 | 0.45 | 0.42 | 0.34 | 0.28 | 0.22 |
| Weighted Avg Shares Out | 29.21M | 29.79M | 29.83M | 29.77M | 29.84M | 29.84M | 29.66M | 29.44M | 29.19M | 28.88M | 28.59M | 28.29M | 28.03M | 27.67M | 27.40M | 27.11M | 26.72M | 26.38M | 26.06M | 25.72M | 25.42M | 25.13M | 24.65M | 24.42M | 24.22M | 24.53M | 24.66M | 24.60M | 24.41M | 24.23M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
| Weighted Avg Shares Out (Dil) | 29.21M | 29.79M | 30.21M | 30.16M | 30.18M | 30.23M | 30.03M | 29.65M | 29.41M | 29.13M | 28.91M | 28.64M | 28.47M | 28.15M | 27.83M | 27.64M | 27.29M | 26.95M | 26.66M | 26.49M | 26.31M | 26.00M | 25.44M | 24.57M | 24.33M | 24.72M | 24.85M | 24.95M | 24.41M | 24.26M | 24.35M | 23.82M | 23.77M | 23.52M | 22.70M | 22.89M | 22.65M | 21.79M | 20.00M |
Tonix Pharmaceuticals to Present at BIO-Europe® 2024
CHATHAM, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer...
BIO-key Secures $910,000 Order to Upgrade Long-Time Financial Services Customer to Enhanced Biometric Customer Identification Technology
HOLMDEL, N.J., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), an innovative provider of workforce and customer identity and access management (IAM) solutions featuring Identity-Bound Biometrics (IBB) for phoneless, tokenless, passwordless and phish-resistant authentication, announced that it...
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
HOUSTON, Oct. 28, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived...
Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Atossa Therapeutics to Participate in Fireside Chat with Karolinska Institute at BIO-EUROPE 2024 to Discuss a Unique Swedish American Collaboration to Prevent Breast Cancer
SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of...
BIO Gears Up for Q3 Earnings: Here's What You Need to Know
Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.
Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2024 on Wednesday, October 30, 2024, following the close of...
BIO-key Accelerates Zero Trust Solutions at Industry-Leading Cybersecurity Conference, ISC² Security Congress 2024
BIO-key Accelerates Zero Trust Solutions at Industry-Leading Cybersecurity Conference, ISC2 Security Congress 2024, incl. hosting a session on Passkeys.
BIO-TECHNE TO HOST CONFERENCE CALL ON OCTOBER 30, 2024, TO ANNOUNCE FIRST QUARTER FISCAL 2025 FINANCIAL RESULTS
MINNEAPOLIS , Oct. 10, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, October 30, 2024, at 8:00 a.m. CDT to review its first quarter fiscal 2025 financial results.
Oncocyte Signs Leading Transplant Centers in US and Germany
IRVINE, Calif., Oct. 02, 2024 – PRISM MediaWire – Oncocyte Corporation (Nasdaq: OCX) (“Oncocyte” or the “Company”), a diagnostics technology company, today announced that its new customers include two leading transplant university hospitals in the U.S. and Germany.
Source: https://incomestatements.info
Category: Stock Reports